DeepCure

DeepCure discovers transformative small molecule therapies for immune and inflammatory diseases. The company uses a chemistry platform that combines AI with advanced physics-based tools to identify truly novel molecules that address unsolved challenges in drug discovery. The pipeline includes an oral STAT6 program with multiple novel scaffolds and an oral BRD4(BD2) program with the first truly selective inhibitor. DeepCure expects to start in clinical trials in 2026.